Name | Number of supported studies | Average coverage | |
---|---|---|---|
macrophage | 8 studies | 23% ± 8% | |
dendritic cell | 8 studies | 34% ± 11% | |
microglial cell | 4 studies | 21% ± 5% | |
extravillous trophoblast | 3 studies | 74% ± 12% |
Insufficient scRNA-seq data for expression of EBI3 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
lung | 96% | 165.43 | 555 / 578 | 74% | 7.10 | 854 / 1155 |
brain | 71% | 82.02 | 1863 / 2642 | 97% | 18.93 | 685 / 705 |
kidney | 79% | 108.63 | 70 / 89 | 87% | 12.96 | 787 / 901 |
breast | 90% | 99.54 | 412 / 459 | 75% | 7.25 | 839 / 1118 |
adrenal gland | 99% | 206.40 | 256 / 258 | 54% | 4.56 | 125 / 230 |
intestine | 93% | 191.23 | 897 / 966 | 57% | 6.79 | 298 / 527 |
prostate | 89% | 106.60 | 217 / 245 | 58% | 3.73 | 292 / 502 |
bladder | 90% | 95.76 | 19 / 21 | 54% | 6.72 | 274 / 504 |
thymus | 57% | 51.47 | 371 / 653 | 84% | 14.88 | 509 / 605 |
stomach | 85% | 94.90 | 304 / 359 | 55% | 7.55 | 158 / 286 |
uterus | 78% | 58.00 | 133 / 170 | 61% | 5.45 | 281 / 459 |
ovary | 63% | 48.93 | 113 / 180 | 68% | 6.75 | 291 / 430 |
pancreas | 58% | 32.02 | 189 / 328 | 67% | 6.97 | 119 / 178 |
liver | 56% | 63.78 | 126 / 226 | 60% | 5.38 | 245 / 406 |
esophagus | 65% | 53.16 | 943 / 1445 | 40% | 3.09 | 74 / 183 |
skin | 35% | 18.52 | 641 / 1809 | 67% | 10.10 | 317 / 472 |
lymph node | 0% | 0 | 0 / 0 | 100% | 254.54 | 29 / 29 |
spleen | 100% | 1767.79 | 241 / 241 | 0% | 0 | 0 / 0 |
adipose | 96% | 176.00 | 1150 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 86% | 126.74 | 1152 / 1335 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 82% | 9.39 | 37 / 45 |
peripheral blood | 69% | 3161.51 | 644 / 929 | 0% | 0 | 0 / 0 |
heart | 60% | 41.63 | 518 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 34% | 2.96 | 27 / 80 |
muscle | 8% | 2.90 | 63 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0019221 | Biological process | cytokine-mediated signaling pathway |
GO_0032729 | Biological process | positive regulation of type II interferon production |
GO_0042088 | Biological process | T-helper 1 type immune response |
GO_0046641 | Biological process | positive regulation of alpha-beta T cell proliferation |
GO_0042098 | Biological process | T cell proliferation |
GO_0006959 | Biological process | humoral immune response |
GO_0005615 | Cellular component | extracellular space |
GO_0005788 | Cellular component | endoplasmic reticulum lumen |
GO_0009897 | Cellular component | external side of plasma membrane |
GO_0043235 | Cellular component | receptor complex |
GO_0005576 | Cellular component | extracellular region |
GO_0005886 | Cellular component | plasma membrane |
GO_0019955 | Molecular function | cytokine binding |
GO_0045523 | Molecular function | interleukin-27 receptor binding |
GO_0005515 | Molecular function | protein binding |
GO_0004896 | Molecular function | cytokine receptor activity |
GO_0005125 | Molecular function | cytokine activity |
Gene name | EBI3 |
Protein name | Interleukin-27 subunit beta (IL-27 subunit beta) (IL-27B) (Epstein-Barr virus-induced gene 3 protein) (EBV-induced gene 3 protein) |
Synonyms | IL27B |
Description | FUNCTION: Associates with IL27 to form the IL-27 interleukin, a heterodimeric cytokine which functions in innate immunity. IL-27 has pro- and anti-inflammatory properties, that can regulate T-helper cell development, suppress T-cell proliferation, stimulate cytotoxic T-cell activity, induce isotype switching in B-cells, and that has diverse effects on innate immune cells. Among its target cells are CD4 T-helper cells which can differentiate in type 1 effector cells (TH1), type 2 effector cells (TH2) and IL17 producing helper T-cells (TH17). It drives rapid clonal expansion of naive but not memory CD4 T-cells. It also strongly synergizes with IL-12 to trigger interferon-gamma/IFN-gamma production of naive CD4 T-cells, binds to the cytokine receptor WSX-1/TCCR. Another important role of IL-27 is its antitumor activity as well as its antiangiogenic activity with activation of production of antiangiogenic chemokines. . |
Accessions | ENST00000221847.6 Q14213 |